Prospective Analysis of Arteriovenous Access (AVA) Use for Continuous Renal Replacement Therapy (CRRT)

Part of paid clinical trials in Greenville, North Carolina.

Sponsor
East Carolina University
Study ID
NCT07447128
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Continuous Renal Replacement Therapy (CRRT)
  • End Stage Kidney Disease (ESRD)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cannulation of permanent dialysis access, for the purpose of delivering continuous renal replacement therapy. — OTHER
    Permanent dialysis access, including arteriovenous fistulas or grafts, will be cannulated using standard dialysis needles for the purpose of delivering continuous renal replacement therapy. CRRT via arteriovenous access will only be performed in ICU settings where nursing staff have at least one year of ICU experience and have completed both study-specific training and institutional CRRT training. Dialysis nurses will perform cannulation of the arteriovenous access according to the standardized operating procedure.

Study Details

Arteriovenous fistula or graft are the ideal hemodialysis access. Nonetheless the most common access type used for Continuous Renal Replacement Therapy (CRRT) is either a temporary or permanent hemodialysis catheter. Recommendations for the use of catheters to deliver CRRT in end stage kidney disease (ESKD) patients are lacking on data and subjective to anecdotal experiences and expert consensus. The repetitive placement of catheters in ESKD patients have shown to increase the chances of central vascular stenosis which is one of the main risk factors that lead to access failure. Also, the repetitive use of dialysis catheters increases the risk for catheter associated infections. Dedicated studies demonstrating the safety and feasibility of using arteriovenous access (AVA) for CRRT are scarce. No screening criteria or algorithm exists to determine the adequate patient and clinical scenario to use AVA for CRRT. Goals of the study: 1. To develop a standard operating procedure for the use of AVA in CRRT. 2. Evaluate the safety and efficacy of using AVA for CRRT.

Key Dates

Start date
Mar 31, 2026
Status verified
Feb 2026
Primary completion
Jun 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Patients with end-stage kidney disease (ESKD) requiring continuous renal replacement therapy (CRRT).
    This cohort will include adult patients with end-stage kidney disease (ESKD) receiving chronic outpatient hemodialysis who are admitted to the Intensive Care Unit (ICU) and require continuous renal replacement therapy (CRRT). Eligible participants must have a mature, functional permanent vascular access used for outpatient hemodialysis, defined as either a functioning arteriovenous fistula (AVF) or a functioning arteriovenous graft (AVG). Patients must meet the inclusion and exclusion criteria prior to enrollment.

Primary Outcome Measure

Access survival [ Time Frame: From initiation of CRRT until discontinuation of CRRT, occurrence of access failure (defined as thrombosis, major access-related complication, or need for temporary dialysis catheter placement), ICU discharge, or up to 30 days after CRRT initiation. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
East Carolina University Medical CenterGreenvilleNorth Carolina27834
Armando F Rodriguez Lopez, MD
[email protected]
9392750483

Find similar trials in Greenville, NC

By research site
East Carolina University Medical Center· Greenville, NC

Related Studies